Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

US10744130B2 · kind B2 · utility

Assignee

• IPSEN BIOPHARM LIMITED · GB

Inventors

• Eliel Bayever · New York, US
• Navreet Dhindsa · Boston, US
• Jonathan Basil Fitzgerald · Arlington, US
• Peter Laivins · Rowayton, US
• Victor Moyo · Ringoes, US
• Clet Niyikiza · ندا, US
• Jaeyeon Kim · Busan, KR

Key dates

• Filing date: Jun 19, 2018
• Grant date: Aug 18, 2020
• Expiry date: Jun 19, 2038

Classification

• Technology area (CPC —): General

Abstract

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.